Boosting GLP-1 by Natural Products

Yaribeygi, Habib; Jamialahmadi, Tannaz; Moallem, Seyed Adel; Sahebkar, Amirhossein

doi:10.1007/978-3-030-73234-9_36

Cited by 5 publications

(3 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This can effectively avoid the adverse effects triggered by a single target. In recent years, many natural products have been reported to have antidiabetic activity [16][17][18]. Acanthopanax senticosus is mainly found in the northeastern region of China.…”

Section: Introductionmentioning

confidence: 99%

A Metabolomics Study of the Effects of Eleutheroside B on Glucose and Lipid Metabolism in a Zebrafish Diabetes Model

Dong,

Chen,

Chi

et al. 2024

Molecules

View full text Add to dashboard Cite

(1) Background: Diabetes is a common metabolic disease that seriously endangers human health. In the present study, we investigated the therapeutic effects of the active ingredient Eleutheroside B (EB) from the traditional Chinese medicine Eleutheroside on diabetes mellitus in a zebrafish model. Concomitant hepatic injury was also analysed, along with the study of possible molecular mechanisms using metabolomics technology. This work should provide some theoretical references for future experimental studies. (2) Methods: A zebrafish diabetes model was constructed by soaking in a 1.75% glucose solution and feeding a high-fat diet. The intervention drug groups were metformin (100 μg∙mL−1) and EB (50, 100, and 150 μg∙mL−1) via water-soluble exposure for 30 days. Glucose, TG, TC, LDL-C, and HDL-C were evaluated in different treatment groups. GLUT4 protein expression was also evaluated in each group, and liver injury was observed by HE staining. Metabolomics techniques were used to investigate the mechanism by which EB regulates endogenous markers and metabolic pathways during the development of diabetes. (3) Results: All EB treatment groups in diabetic zebrafish showed significantly reduced body mass index (BMI) and improved blood glucose and lipid profiles. EB was found to upregulate GLUT4 protein expression and ameliorate the liver injury caused by diabetes. Metabolomics studies showed that EB causes changes in the metabolic profile of diabetic zebrafish. These were related to the regulation of purine metabolism, cytochrome P450, caffeine metabolism, arginine and proline metabolism, the mTOR signalling pathway, insulin resistance, and glycerophospholipid metabolism. (4) Conclusions: EB has a hypoglycaemic effect in diabetic zebrafish as well as significantly improving disorders of glycolipid metabolism. The mechanism of action of EB may involve regulation of the mTOR signalling pathway, purine metabolism, caffeine metabolism, and glycerophospholipid metabolism.

show abstract

Section: Introductionmentioning

confidence: 99%

A Metabolomics Study of the Effects of Eleutheroside B on Glucose and Lipid Metabolism in a Zebrafish Diabetes Model

Dong,

Chen,

Chi

et al. 2024

Molecules

View full text Add to dashboard Cite

show abstract

“…Glucagon-like peptide-1 (GLP-1) is an endogenous incretin secreted by small intestinal L cells, consisting of two bioactive isoforms: GLP-1 (7-37) and GLP-1 (7-36). GLP-1 is rapidly degraded by an enzyme named dipeptidyl peptidase-IV (DPP-4), converting to bioinactive products GLP-1 (9-36) and GLP-1 (9-37) ( 1 – 3 ), which have a very low affinity for GLP-1 receptor (GLP-1R) and have no insulin secretion effect. Endogenous GLP-1 has a short plasma half-life of about 2-3 min ( 4 – 6 ).…”

Section: Introductionmentioning

confidence: 99%

“…GLP-1R agonists (GLP-1RAs) are a group of GLP-1 analogues that are resistant to DPP4-mediated degradation, working through activating GLP-1R and its downstream signaling ( 3 , 17 , 18 ). GLP-1RA is widely used to treat type 2 diabetes by enhancing insulin production, and they also have the added benefit of suppressing appetite and losing weight ( 19 , 20 ).…”

Section: Introductionmentioning

confidence: 99%

GLP-1 receptor agonist as a modulator of innate immunity

Mei

Wei

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Glucagon-like peptide-1 (GLP-1) is a 30-amino acid hormone secreted by L cells in the distal ileum, colon, and pancreatic α cells, which participates in blood sugar regulation by promoting insulin release, reducing glucagon levels, delaying gastric emptying, increasing satiety, and reducing appetite. GLP-1 specifically binds to the glucagon-like peptide-1 receptor (GLP-1R) in the body, directly stimulating the secretion of insulin by pancreatic β-cells, promoting proliferation and differentiation, and inhibiting cell apoptosis, thereby exerting a glycemic lowering effect. The glycemic regulating effect of GLP-1 and its analogues has been well studied in human and murine models in the circumstance of many diseases. Recent studies found that GLP-1 is able to modulate innate immune response in a number of inflammatory diseases. In the present review, we summarize the research progression of GLP-1 and its analogues in immunomodulation and related signal pathways.

show abstract

The role of nanosystems in the delivery of glucose-lowering drugs for the preemption and treatment of diabetes-associated atherosclerosis

Conroy,

McCann,

Zhang

et al. 2024

American Journal of Physiology-Cell Physiology

View full text Add to dashboard Cite

Diabetes is one of the most prevalent diseases worldwide. In recent decades, type-2 diabetes has become increasingly common, particularly in younger individuals. Diabetes leads to many vascular complications, including atherosclerosis. Atherosclerosis is a cardiovascular disease characterized by lipid-rich plaques within the vasculature. Plaques develop over time, restricting blood flow; and can therefore be the underlying cause of major adverse cardiovascular events, including myocardial infarction and stroke. Diabetes and atherosclerosis are intrinsically linked. Diabetes is a metabolic syndrome which accelerates atherosclerosis and increases the risk of developing other co-morbidities, such as Diabetes-associated Atherosclerosis (DAA). Gold-standard anti-diabetic medications focus on attenuating hyperglycemia. Though recent evidence suggests that glucose-lowering drugs may have broader applications, beyond diabetes-management. This review mainly evaluates the role of glucagon-like peptide-1 receptor agonists (GLP-1 RA), such as Liraglutide and Semaglutide in DAA. These drugs mimic gut hormones (incretins), which inhibit glucagon secretion whilst stimulating insulin secretion, thus improving insulin sensitivity. This facilitates delayed gastric emptying and increased patient satiety; hence they are also indicated for the treatment of obesity. GLP-1 RAs have significant cardioprotective effects, including decreasing low-density lipoprotein (LDL)-cholesterol and triglycerides levels. Liraglutide and Semaglutide have specifically been shown to decrease cardiovascular risk. Liraglutide has displayed a myriad of anti-atherosclerotic properties, with the potential to induce plaque regression. This review aims to address how glucose-lowering medications can be applied to treat diseases other than diabetes. We specifically focus on how nanomedicines can be used for the site-specific delivery of anti-diabetic medicines for the treatment of diabetes-associated atherosclerosis.

show abstract

Boosting GLP-1 by Natural Products

Cited by 5 publications

References 80 publications

A Metabolomics Study of the Effects of Eleutheroside B on Glucose and Lipid Metabolism in a Zebrafish Diabetes Model

A Metabolomics Study of the Effects of Eleutheroside B on Glucose and Lipid Metabolism in a Zebrafish Diabetes Model

GLP-1 receptor agonist as a modulator of innate immunity

The role of nanosystems in the delivery of glucose-lowering drugs for the preemption and treatment of diabetes-associated atherosclerosis

Contact Info

Product

Resources

About